CERUS CORP (CERS) Form 10-Q — Jul 30, 2026
Cerus Corporation reported total revenue of $123.2 million for the six months ended June 30, 2026, representing a 13% increase compared to the prior year period. This growth was primarily driven by a 16% increase in product revenue to $111.1 million, fueled by higher sales volumes of disposable platelet and plasma kits and INTERCEPT Fibrinogen Complex (IFC) kits to U.S. customers. The company significantly narrowed its net loss to $4.6 million for the six-month period, an improvement from the net loss of $13.4 million reported in the same period of 2025.
Key figures
- Revenue
- 123196000
- Cash Position
- 17980000
- Shares Outstanding
- 201524898
- Product revenue 6mo
- 111102000
- Short term investments
- 38284000
- Government contract revenue 6mo
- 12094000
Price after filing
Close on the filing date to close N calendar days later (from $2.92). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.